You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Central Nervous System Lymphoma（PCNSL）

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

Not yet recruiting
  • Non-Hodgkin Lymphoma
  • Cologne, Germany
    University of Cologne
Oct 14, 2022

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Micro and Macroscopic Level of Primary Central Nervous System

Active, not recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • Tumor samples and MRI
  • Paris, France
    Groupe Hospitalier La Pitié Salpêtrière
Feb 17, 2022

Refractory/Recurrent Primary CNS Lymphoma (PCNSL) Trial in United States (Ibrutinib, Copanlisib)

Recruiting
  • Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
  • Basking Ridge, New Jersey
  • +6 more
Jul 27, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

Part A: Relapsed or Refractory Primary CNS Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL Trial in United

Recruiting
  • Part A: Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Part B: Newly Diagnosed, Treatment naïve PCNSL
  • Duarte, California
  • +29 more
Jun 15, 2022

Factors in Patients With Primary Central Nervous System Lymphoma

Recruiting
  • PCNSL
  • Survival Analysis
  • prognostic marker
  • Zhengzhou, Henan, China
    Zhengzhou university
Dec 12, 2021

PCNSL Trial in Shanghai (Zanubrutinib, Rituximab, Methotrexate)

Not yet recruiting
  • PCNSL
  • Shanghai, Shanghai, China
    Ruijin Hospital
Jun 8, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +2 more
May 19, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL) Trial in Manchester,

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • +7 more
  • Manchester, United Kingdom
  • +2 more
Aug 11, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial (F520)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • (no location specified)
Oct 19, 2020

Primary CNS Lymphoma (PCNSL) Trial (Rituximab)

Not yet recruiting
  • Primary Central Nervous System Lymphoma (PCNSL)
  • (no location specified)
Dec 24, 2020

Primary CNS Lymphoma, PCNSL, Non Hodgkin Lymphoma Trial in Guandong, Guangzhou (Methotrexate, Ibrutinib, Temozolomide)

Recruiting
  • Primary Central Nervous System Lymphoma
  • +2 more
  • Guandong, Guangdong, China
  • +2 more
Apr 6, 2022

Primary CNS Lymphoma Trial in Stuttgart (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix,

Recruiting
  • Primary Central Nervous System Lymphoma
  • Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix
  • Control intervention: four courses of MATRix
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
Feb 15, 2022

Lymphoma Trial in Worldwide (Nivolumab)

Completed
Has Results
  • Lymphoma
  • Birmingham, Alabama
  • +49 more
Nov 24, 2021

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Lymphoma, B-Cell Trial in Taipei (non-intervention)

Recruiting
  • Lymphoma, B-Cell
  • non-intervention
  • Taipei, Taiwan
    National Taiwan University Hospital
Jun 14, 2021

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

Recruiting
  • Primary Central Nervous System Lymphoma
  • the dose-escalation phase
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022